Ask Onix
Weight-loss medications transform lives but aren't a standalone cure
New appetite-suppressing drugs like semaglutide and tirzepatide have delivered dramatic results for individuals battling obesity, yet specialists caution that sustained weight loss demands ongoing treatment and lifestyle adjustments.
Personal breakthroughs and growing popularity
Sarah Le Brocq, who has struggled with obesity for most of her adult life, experienced a profound shift after starting weight-loss medication over two years ago. She shed nearly 51 kilograms (112 pounds) and regained energy for activities she previously couldn't manage. "I've just got more energy, I'm doing things I couldn't do before... it's kind of given me a new freedom in life again," she told the BBC's Inside Health.
Le Brocq is among millions now using drugs like Ozempic (semaglutide) and Mounjaro (tirzepatide), which mimic hormones signaling fullness to the brain. These medications have sparked what experts call a "new era" in obesity treatment, with some hailing them as "miracle drugs" for their effectiveness. However, their rapid adoption-including a booming private market for non-obese users-has raised concerns about overreliance and long-term consequences.
How the drugs work-and why weight rebounds
GLP-1 and GIP receptor agonists suppress appetite by mimicking gut hormones that regulate satiety. Most users begin losing weight within weeks, with clinical trials showing 14-20% reductions over 72 weeks. Yet 10-15% of patients see minimal results, and stopping the drugs often leads to rapid weight regain.
A recent study found that individuals regained 1.5 kilograms (3.3 pounds) within eight weeks of discontinuing medication, with weight continuing to climb over time. Another analysis revealed that 60% of lost weight returns within a year of stopping treatment. Experts attribute this to "food noise"-intrusive thoughts about eating-and hormonal adaptations that slow metabolism and increase appetite after weight loss.
"If these biological defenses are strong enough, they can blunt the drug's effectiveness,"
David Cummings, Professor of Medicine, University of Washington
Lifestyle changes remain critical
While the drugs act as a "chemical shield" against obesogenic environments, experts stress that behavioral changes are essential for lasting results. Naveed Sattar, a professor of cardiometabolic medicine at the University of Glasgow, notes that some patients may reduce dosages or use medications intermittently if they adopt healthier diets. However, most will likely require ongoing treatment due to persistent environmental triggers like cheap, calorie-dense foods.
The World Health Organization (WHO) warns that medication alone cannot "reverse the obesity challenge," emphasizing the need for early interventions, screening, and healthier food environments. Amanda Daley, a professor of behavioral medicine at Loughborough University, underscores the importance of "wraparound care," including dietary support and physical activity, to prevent nutritional deficiencies and muscle loss.
Side effects and unanswered questions
Common side effects include gastrointestinal issues, pancreatitis, and gallstones. Recent research also links the drugs to bone and joint conditions, as well as muscle loss in sedentary users. Long-term data remain limited, particularly regarding pregnancy outcomes, as weight-loss medications are not recommended during gestation.
Despite these risks, experts argue that the benefits outweigh the harms for individuals with obesity-related conditions like heart disease, diabetes, and sleep apnea. Studies involving two million people found additional health improvements, including reduced risks of dementia, infections, and substance abuse.
Innovations and future challenges
Emerging drugs like Eli Lilly's retatrutide, which targets three hunger-regulating hormones, have shown even greater promise, with early trials reporting nearly 29% weight loss over 68 weeks. Yet experts caution that these medications are just one tool in a broader strategy to combat obesity.
Researchers at Stanford University are exploring "microsteps"-small, manageable behavioral changes like swapping sugary drinks for water or taking short walks-to support long-term health. Maya Adam, a clinical associate professor at Stanford, describes these as "too small to fail," emphasizing their potential to create lasting habits.
"Achieving your best health involves a lot more than pharmacotherapy alone,"
Maya Adam, Stanford School of Medicine
Daley and other experts advocate for policy changes to improve food environments, reducing the need for weight-loss drugs in future generations. Until then, they urge better communication about the challenges of maintaining weight loss after stopping medication and the importance of integrated care.
